Contineum Therapeutics, Inc. Class A Common Stock (CTNM)
Healthcare
Biotechnology
15.50 $
-1.7%
vs. previous close
Closing price · As of: 31. Jul 2026
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -12 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
| Tick rows to compare them in a chart (up to 4) | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -5.4 | -11 | -8.1 | -8.4 | -6.2 | -10 | -14 | -16 | -12 | -13 | -16 | -12 | -53 | |
| 0.0 | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.4 | |
| 0.5 | 0.8 | 0.8 | 1.5 | 2.3 | 2.3 | 2.6 | 2.4 | 2.6 | 2.5 | 3.8 | 3.8 | 13 | |
| 1.1 | -2.8 | 0.3 | -0.2 | 2.3 | 3.0 | -1.1 | -1.9 | -2.3 | -0.7 | -5.9 | 5.9 | -3.0 | |
| 0.0 | 0.3 | 0.1 | 0.1 | 0.1 | 0.2 | 0.0 | 0.0 | 0.1 | 0.0 | 0.3 | 0.0 | 0.5 | |
| -39 | 9.0 | 8.7 | -39 | -30 | -9.4 | 15 | 14 | 15 | -47 | -39 | 4.9 | -67 | |
| – | 0.0 | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | 0.0 | 0.0 | – | – | – | – | – | – | – | |
| 10 | -0.3 | 0.1 | 108 | 0.0 | 0.6 | 0.0 | 0.1 | 19 | 93 | 0.1 | 1.2 | 114 | |
| -35 | -2.0 | 0.7 | 61 | -36 | -19 | 0.5 | -1.7 | 22 | 33 | -55 | -5.4 | -6.1 | |
| -5.4 | -11 | -8.3 | -8.5 | -6.3 | -10 | -14 | -16 | -12 | -13 | -17 | -12 | -53 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.